SHASQI

Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.